Daily Archives: March 24, 2020

SNOMED CT global clinical terminology is introduced in Germany through the Medical Informatics Initiative

London, United Kingdom, March 24, 2020 (GLOBE NEWSWIRE) — The Medical Informatics Initiative (MII) formally announced a relationship with SNOMED International Wednesday March 18, 2020.  As of last week, the Federal Ministry of Research has given MII participants nationwide a license to use SNOMED CT.

Owned and maintained by SNOMED International, SNOMED CT is the world’s largest clinical terminology, representing a collection of more than 350,000+ clinical concepts and built upon ontological principles and of particular use when applied in research and planning capacities.  SNOMED CT’s primary purpose is to support all healthcare professionals in their recording and sharing of detailed patient information within Electronic Health Records (EHRs) and across healthcare communities globally. Its ontological foundations allow SNOMED CT data to support detailed data analytics to meet a variety of use cases from local requirements to population-based analytics.

With the help of SNOMED CT, programs can translate different medical terms into an internationally standardized numerical code. In this way, clinical data from different countries can be compared and used for research.  This creates the prerequisites for treating diseases more effectively in the future, recognizing them faster and supporting prevention. The networking of routine care data and top medical research has great potential – for better medical treatment and for strengthening Germany as a business and science location.

With a strong presence in Europe, MII’s license joins the initiative with 24 Members across Europe in the adoption and use of SNOMED CT.  Currently within Germany, there also exist a large number of additional SNOMED CT affiliate licensees, representing a mixture of large vendors and local development licenses which have been provided free of charge for the time limited period of a project.

As part of the Medical Informatics Initiative (MII) funded by the Federal Ministry of Education and Research (BMBF), the terminology standard can now be used nationwide.  This “pilot license” will be initially limited to MII participants and project partners. During the course of the agreement, the German Federal Ministry of Education and Research (BMBF) bears applicable license fees.  The technology and method platform for networked medical research (TMF e.V.) will serve as the National Release Center and, as the MII coordination point, will organize and support the nationwide cooperation of the MII participants.
SNOMED International is pleased to support the use of SNOMED CT throughout Germany and specifically within the Medical Informatics Initiative.  CEO Don Sweete offers, “This is an exciting development which will benefit healthcare professionals and patients throughout the country. German licensees are joining a global SNOMED CT community which extends access to dedicated regional resources, release support, education, open source tooling and software, and in-person engagement opportunities.”  With a complement of 39 Members, SNOMED CT now represents approximately one third of the global population. Adding to that complement with our affiliate licensees, SNOMED CT is now used in more than ninety countries globally.

About the The Medical Informatics Initiative

The medical informatics initiative was created to close the gap between research and healthcare.  All of Germany’s university hospitals have joined forces with research institutions, businesses, health insurers, and patient advocacy groups to create a framework that harnesses research findings to the direct benefit of patients.  The German Federal Ministry of Education and Research (BMBF) is investing around 160 million euros in the programme through 2021. Learn More..

About SNOMED International

SNOMED International is a not-for-profit organization that owns and develops SNOMED CT, the world’s most comprehensive healthcare terminology product.  We play an essential role in improving the health of humankind by determining standards for a codified language that represents groups of clinical terms.  This enables healthcare information to be exchanged globally for the benefit of patients and other stakeholders. We are committed to the rigorous evolution of our products and services, to deliver continuous innovation for the global healthcare community.  SNOMED International is the trading name of the International Health Terminology Standards Development Organisation. Learn More…

Kelly Kuru
SNOMED International
1 416 566 8725

Bombardier Announces Temporary Suspension of Work at its Canadian Operations; Suspends 2020 Financial Guidance

MONTREAL, March 24, 2020 (GLOBE NEWSWIRE) — Bombardier (TSX: BBD.B) today announced that in support of the recent mandates from the Governments of Quebec and Ontario to help slow the spread of the COVID-19 pandemic, it will suspend all non-essential work at most of its Canadian based operations starting this evening at 11:59 pm until April 26, 2020, inclusively. This suspension includes Bombardier’s aircraft and rail production activities in the provinces of Quebec and Ontario.

Employees impacted by these temporary shutdowns will be placed on furlough, as will corporate office employees whose support functions are less critical in the short-term. During this furlough period, Bombardier’s CEO and senior leadership team will forgo their pay, and the Chairman and members of Bombardier’s Board of Directors have agreed to forgo board compensation for the remainder of 2020.

Bombardier is also suspending its 2020 financial outlook as it evaluates the impact of temporarily closing its Canadian operations, as well as other actions being taken in response to the COVID-19 pandemic.

“Since the corona virus outbreak, the company has been focused on keeping our employees safe, serving our customers to the best of our ability during these difficult times and taking the necessary actions to protect our business for the long term,” said Pierre Beaudoin, Chairman of the Board of Directors, Bombardier Inc. “In addition to the actions announced today, Bombardier has cut all discretionary spending, is continuing the work on closing the previously announced transactions and is pursuing additional measures to enhance liquidity.”

About Bombardier
With over 60,000 employees across two business segments, Bombardier is a global leader in the transportation industry, creating innovative and game-changing planes and trains. Our products and services provide world-class transportation experiences that set new standards in passenger comfort, energy efficiency, reliability and safety.

Headquartered in Montréal, Canada, Bombardier has production and engineering sites in over 25 countries across the segments of Aviation and Transportation. Bombardier shares are traded on the Toronto Stock Exchange (BBD). In the fiscal year ended December 31, 2019, Bombardier posted revenues of $15.8 billion. News and information are available at bombardier.com or follow us on Twitter @Bombardier.

For Information
Jessica McDonald
Advisor, Media Relations and Public Affairs
Bombardier Inc.
+514 861 9481

Patrick Ghoche
Vice President, Corporate Strategy
and Investor Relations
Bombardier Inc.
+514 861 5727

Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant

  • Dynavax is providing CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, to support the rapid development of Clover’s COVID-19 vaccine
  • Clover advancing evaluation of its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer)

EMERYVILLE, Calif. and CHENGDU, China, March 24, 2020 (GLOBE NEWSWIRE) — Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and Clover Biopharmaceuticals, a China-based global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, today announced that they have entered into a research collaboration to develop a vaccine candidate to prevent COVID-19.  Clover is advancing evaluation of its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer) in preclinical studies.  Dynavax is providing technical expertise and the company’s proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018, to support this initiative.

In late-January 2020, upon knowing the genomic DNA sequence of the newly identified SARS-CoV-2 virus, which causes a disease named COVID-19, Clover scientists started designing the viral spike (S)-protein construct and completed its gene synthesis. Utilizing its patented Trimer-Tag© technology, Clover has produced a COVID-19 S-Trimer subunit vaccine candidate that resembles the native trimeric viral spike via a rapid mammalian cell-culture based expression system.  Having one of the largest in-house, commercial-scale cGMP biomanufacturing capabilities in China, Clover could potentially rapidly scale-up and produce large-quantities of a new coronavirus vaccine.

“At Clover, we are eager to begin evaluating the combination of our S-Trimer vaccine candidate and Dynavax’s CpG 1018 adjuvant, as we believe adjuvants could play an important role in developing a successful and widely-available vaccine for this pandemic,” said Joshua Liang, Chief Strategy Officer at Clover and co-inventor of COVID-19 S-Trimer vaccine. “Leveraging our proprietary© Trimer-Tag technology, S-Trimer is being rapidly developed to support global efforts in combating the current and any future coronavirus outbreaks.”

CpG 1018 is the adjuvant used in HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration (FDA). Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B. CpG 1018 provides a well‑developed technology and a significant safety database, potentially accelerating the development and large-scale manufacturing of a COVID-19 vaccine.

“Successfully responding to this public health emergency will require a collaborative approach, combining technologies and sharing data, to rapidly develop a vaccine to prevent COVID-19,” commented Ryan Spencer, Chief Executive Officer of Dynavax. “We are proud to contribute to this global effort with the goal of supporting rapid development and enabling large-scale manufacturing through the utilization of CpG 1018 which has already been successfully implemented in an approved, marketed vaccine in the U.S.”

About the Novel Coronavirus SARS-CoV-2 (and COVID-19 Disease)
SARS-CoV-2 is a new coronavirus identified in late 2019 and belongs to a family of enveloped RNA viruses that include MERS and SARS, both of which caused serious human infections of respiratory system.  The virus, which causes a disease named COVID-19, has never before been found in humans. Since this outbreak was first reported in late-2019, the virus has infected over 334,000 people and has caused over 14,600 reported deaths (as of 23 March 2020). It has been declared a pandemic by the World Health Organization (WHO).  Currently there is no vaccine available for COVID-19.

About COVID-19 S-Trimer Vaccine
Utilizing Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. The trimeric S protein of SARS-CoV-2 is responsible for binding to host cell surface receptor ACE2 and subsequent viral entry, making it the primary target antigen for vaccine development. S-Trimer resembles the native trimeric viral spike protein and is produced via a rapid mammalian cell-culture based expression system.

About Clover Biopharmaceuticals
China based Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases, as well as viral vaccines. Having raised more than US$ 100 million in total capital since 2016, Clover is utilizing its proprietary Trimer-Tag© technology platform to develop novel biologics targeting trimerization-dependent pathways. Additionally, Clover is leveraging its in-house cGMP biomanufacturing capabilities to develop select biosimilars. For more information, please visit our website:  www.cloverbiopharma.com.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company launched its first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], in February 2018, following U.S. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.  Dynavax is also advancing CpG 1018 as an advanced vaccine adjuvant through research collaborations and partnerships.  For more information, visit www.dynavax.com and follow the company on LinkedIn.

Forward-Looking Statements
This press release contains “forward-looking” statements, including statements regarding the potential to develop a COVID-19 vaccine and to do so on an accelerated basis.  Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in vaccine research and development, including the timing of completing development, the results of clinical trials, and whether and when the vaccine will be approved for use, as well as other risks detailed in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 as well as discussions of potential risks, uncertainties and other important factors in our other filings with the U.S. Securities and Exchange Commission. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Information on Dynavax’s website at www.dynavax.com is not incorporated by reference in our current periodic reports with the SEC.

Contact – Clover Biopharmaceuticals
Joshua Liang, +86 028-63925705

Contacts – Dynavax
Nicole Arndt, Senior Manager, Investor Relations

Derek Cole, President
Investor Relations Advisory Solutions

HP Helps Business Professionals Stay Productive at Home with Printing for Months Without Reloading

HP Neverstop Laser, designed for small businesses

HP Neverstop Laser, designed for small businesses

Introducing HP Neverstop Laser with 7X more printing in the box6, first-of-its-kind, easy toner reload for less than one cent per page5

PALO ALTO, Calif., March 24, 2020 (GLOBE NEWSWIRE) — HP Inc. today announced global availability of HP Neverstop Laser, the world’s first toner tank1.

“As business people shift to work from home, they need technology that is easy to use and printing with fewer interruptions – HP Neverstop delivers both,” said Tuan Tran, President, Printing, HP Inc. “This means printing for months9, without having to refill toner, at the lowest cost per page.”

HP Neverstop being filled with HP Toner reload kit

HP Neverstop being filled with HP Toner reload kit

Key features include:

  • Get more toner in-box delivering up to 7X more pages than in-class lasers6
    No cartridge replacement interruptions1 with up to 5,000 pages of printing included before your first toner reload6.
  • Lowest cost for Original HP Toner in-class5. Less than 1 cent per page5
    Get legendary quality, reliability and precision printing now and every time you reload.
  • Save every time you reload7
    HP Toner Reload Kits cost less, with up to 2.5X more pages compared to in-class HP cartridges7.  Quickly restore toner levels with up to 2,500 pages7 – no mess, no stress1. Watch how.
  • Connected and mobile
    °  Easy mobile scanning and printing, secure fax sending, seamless Toner Reload Kit ordering and Smart Tasks document organization with the HP Smart App, which allows on-the-go access from virtually anywhere8.
  • Certified energy-saving and Sustainable
    HP Neverstop Laser’s low emission, clean air quality technology is both Blue Angel and Energy Star 3.0 certified.
    °  Made with more than 25 percent recycled plastic by weight while the toner reload kit is made of 75 percent recycled plastic by weight.
    °  Up to an 84 percent smaller environmental footprint over its life2 than standard laser printers due to continuous toner supply system (CTSS)3 and recycled content4.
HP Neverstop Laser

HP Neverstop Laser

Pricing and Availability
HP Neverstop Laser is available for purchase now globally from select retailers. Pricing and more information can be found at hp.com/neverstop.

About HP Inc.
HP Inc. (NYSE: HPQ) creates technology that makes life better for everyone, everywhere. Through our product and service portfolio of personal systems, printers and 3D printing solutions, we engineer experiences that amaze. More information about HP Inc. is available at www.hp.com.

Jaclyn Montalvo, HP


©Copyright 2020 HP Development Company, L.P. The information contained herein is subject to change without notice. The only warranties for HP products and services are set forth in the express warranty statements accompanying such products and services. Nothing herein should be construed as constituting an additional warranty. HP shall not be liable for technical or editorial errors or omissions contained herein.

HP Neverstop: World’s first cartridge-free toner tank laser printer offers fast and clean refill experience: Constant toner self-reload using imaging-drum-in-place OEM toner supplies compared to majority of worldwide OEM monochrome laser printers <$250 USD and MFPs priced <$350 USD as of Nov 15, 2018.  HP internal research & Keypoint Intelligence-Buyers Lab 2019 study commissioned by HP.  Market share as reported by IDC CYQ2 2018 Hardcopy Peripherals Tracker, 2018Q2 Release.  For details, see keypointintelligence.com/HPNeverstop 
HP Neverstop: 84 percent smaller environmental footprint over its life2 than standard laser printers due to its continuous toner supply system (CTSS)3 and recycled content4
Environmental footprint includes printer and supplies: raw material extraction and processing, printer manufacturing and transportation as well as electricity, drum and reload kit use and end-of-use.  Does not include paper use.
Carbon dioxide equivalent (CO2e) savings of HP Neverstop with CTSS Technology vs. HP LaserJet Pro M15a and HP LaserJet Pro MFP M28a Printers is based on the average lifetime use of printing 50,000 pages. Peer-reviewed life cycle assessment models commissioned by HP and conducted by thinkstep.  Results reviewed by HP internal LCA experts. Analysis completed June 27, 2019.
HP Neverstop is made with more than 25 percent recycled plastic by weight of plastic.
Lowest cost for Original HP Toner in-class.  Less than 1 cent per page: Compared to the majority of in-class MFPs cartridge devices <$330 USD. Keypoint Intelligence – Buyers Lab February 2020 research study commissioned by HP, based on research survey of printer manufacturers’ and resellers’ published specifications, pricing, and data sheets as of 02/03/2020. Market share as reported by IDC Quarterly Hardcopy Peripherals Tracker – Final Historical 2019Q3. Total cost of ownership based on printer MSRP, in-box supplies, and highest-capacity replacement OEM supplies to print 234 pages a month over 4 years. Monthly page volume based on internal HP estimates. For details, please see: keypointintelligence.com/HPNeverstopUS.
Get more toner in-box delivering up to 7x more pages than in-class lasers: Actual yield varies considerably based on content of printed pages and other factors. Average based on included OEM supplies, ISO/IEC 19752 and continuous printing. Additional printed pages require toner reload. For details see www.hp.com/go/learnaboutsupplies.  Compared to majority of in-class monochrome laser printers and MFPs $250 to $300 & €260 to €300 sold in developed markets.  HP internal research based on survey of printer manufacturers published in-box yield as of Sept 28, 2019.  Market share as reported by IDC Quarterly Hardcopy Peripherals Tracker – Final Historical 2019Q2.
HP Toner Reload Kits cost a lot less, with up to 2.5X more pages compared to in-class HP cartridges: Based on internal HP comparison of MSRP/[MRSP equivalent for EMEA region] and cost-per-page of in-class HP LaserJet Pro M15 and HP LaserJet Pro MFP M28 with standard-fill HP 44A/48A Black Original LaserJet Toner Cartridge, as of March 2020. For details see www.hp.com/go/learnaboutsupplies.
Printing, scanning and copying from virtually anywhere: Requires the HP Smart app download. For details on local printing requirements see hp.com/go/mobileprinting. Certain features/software are available in English language only. Internet access required and must be purchased separately. Fax capabilities are for sending a fax only, and may require additional purchase. For more information, see hpsmart.com/mobile-fax.
Printing for Months without Reloading: Based on HP internal research that 90% of US customers AMPV (Average Monthly Printing Volume) is under 486 pages per month, which equals about 10.2 month for 5000 pages.

Photos accompanying this announcement are available at:




VICTOR, N.Y., March 24, 2020 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, today responded to the outcome of a recent public consultation in Mexicali, Baja California (Mexico) which voiced opposition to the company’s plans to build a new brewery in the city.

“We will continue working with local authorities, government officials and members of the community on next steps related to our brewery construction project in Mexicali and options elsewhere in Mexico,” said Bill Newlands, president and chief executive officer at Constellation Brands. “In the meantime, it’s important to note that we have ample capacity, based on current growth forecasts and production capabilities at our Nava brewery and soon to be completed expansion in Obregon, to continue fueling the growth of our beer business in the medium-term. We’ve had a positive, mutually beneficial relationship with Mexico for more than 30 years and we fully expect this to continue.”

Since 2013, Constellation has made significant investments in its production operations throughout Mexico to support the robust growth of its import beer business. The company will leverage these investments and other options to continue meeting the needs of U.S. consumers over the long-term.

This news release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements. These statements may relate to business strategy, future operations, prospects, and plans and objectives of management, the company’s brewing capacity, and the supply of its products available for purchase by its consumers, as well as information concerning the expected actions of third parties. All forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those set forth in, or implied by, such forward-looking statements.

The forward-looking statements are based on management’s current expectations and should not be construed in any manner as a guarantee that such results will in fact occur. All forward-looking statements speak only as of the date of this news release and Constellation Brands undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

In addition to risks and uncertainties associated with ordinary business operations, the forward-looking statements contained in this news release are subject to other risks and uncertainties, including the accuracy of all projections and other factors and uncertainties disclosed from time-to-time in the company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended February 28, 2019, as supplemented by the company’s Quarterly Report on Form 10-Q for the fiscal quarter ended May 31, 2019, which could cause actual future performance to differ from current expectations.

At Constellation Brands (NYSE: STZ and STZ.B), our mission is to build brands that people love because we believe sharing a toast, unwinding after a day, celebrating milestones, and helping people connect, are Worth Reaching For. It’s worth our dedication, hard work, and the bold calculated risks we take to deliver more for our consumers, trade partners, shareholders, and communities in which we live and work. It’s what has made us one of the fastest-growing large CPG companies in the U.S. at retail, and it drives our pursuit to deliver what’s next.

Today, we are a leading international producer and marketer of beer, wine, and spirits with operations in the U.S., Mexico, New Zealand, and Italy. Every day, people reach for our high-end, iconic imported beer brands such as Corona Extra, Corona Light, Corona Premier, Modelo Especial, Modelo Negra, and Pacifico, and our high-quality premium wine and spirits brands, including the Robert Mondavi brand family, Kim Crawford, Meiomi, The Prisoner brand family, SVEDKA Vodka, Casa Noble Tequila, and High West Whiskey.

But we won’t stop here. Our visionary leadership team and passionate employees from barrel room to boardroom are reaching for the next level, to explore the boundaries of the beverage alcohol industry and beyond. Join us in discovering what’s Worth Reaching For.

To learn more, follow us on Twitter @cbrands and visit www.cbrands.com.

Mike McGrew 773-251-4934 / michael.mcgrew@cbrands.com Patty Yahn-Urlaub 585-678-7483 / patty.yahn-urlaub@cbrands.com
Amy Martin 585-678-7141 / amy.martin@cbrands.com Bob Czudak 585-678-7170 / bob.czudak@cbrands.com

A downloadable PDF copy of this news release enhanced with multimedia links can be found here: http://ml.globenewswire.com/Resource/Download/c926458b-7206-4409-b886-34907fcf2c74